Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06538480 · ClinicalTrials.gov registry record · Phase 4

Zopa Retreatment and Vector Shedding in Adults With RRP

A Phase 4 study of Recurrent Respiratory Papillomatosis and Papillomavirus Infection, sponsored by Precigen.

Recruiting
Registry status
Phase 4
Development phase
30
Enrollment target
3
Study locations

NCT06538480 is a Phase 4 study of Recurrent Respiratory Papillomatosis and Papillomavirus Infection that is actively recruiting participants, run by Precigen. The registered enrollment target is 30 participants, below the 34-participant average among 6 other Recurrent Respiratory Papillomatosis trials with a reported enrollment target (12% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06538480, a Phase 4 study of Recurrent Respiratory Papillomatosis and Papillomavirus Infection, is actively recruiting participants, sponsored by Precigen.

RECRUITING
Registry status
Phase 4
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, feces, skin, and nasal tissue; Cohort 2 to assess the complete response rate following retreatment.

Conditions Studied

Recurrent Respiratory Papillomatosis Papillomavirus Infection Papillomaviridae

Interventions

  • DRUG Zopapogene imadenovec (Zopa)

Study Locations (3)

Georgia

  • Winship Cancer Institute, Emory University - Atlanta

Maryland

  • National Institute of Health - Bethesda

Ohio

  • University of Cincinnati - Cincinnati

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-07-11
Est. Completion 2028-12-02
Phase Phase 4

Sponsor

Precigen

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06538480

The ClinicalTrials.gov registry entry for NCT06538480 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 34-participant average among 6 other Recurrent Respiratory Papillomatosis trials with a reported enrollment target (12% lower). The listed sponsor is Precigen, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Recurrent Respiratory Papillomatosis appearing as the primary indexed condition, and to 1 intervention - of which Zopapogene imadenovec (Zopa) is the first listed.

NCT06538480 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Georgia, Maryland, Ohio.

Frequently Asked Questions

What is clinical trial NCT06538480 about?

NCT06538480 is a clinical study titled "Zopa Retreatment and Vector Shedding in Adults With RRP". This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, fece...

What is the current status of trial NCT06538480?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2024-07-11. Estimated completion is 2028-12-02.

What conditions does trial NCT06538480 study?

This clinical trial studies the following conditions: Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae.

What interventions are being tested in trial NCT06538480?

The interventions under investigation include: Zopapogene imadenovec (Zopa) (DRUG).

Who is sponsoring clinical trial NCT06538480?

This trial is sponsored by Precigen, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06538480 being conducted?

This trial has 3 study locations across Georgia, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Respiratory Papillomatosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Respiratory Papillomatosis

All registered trials for this condition

Papillomavirus Infection

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.